These robust data show that XR-NTX helped opioid dependent patients become drug-free with just one injection each month, stated Dr. Herbert Kleber, Professor of Psychiatry, Director, Division on Substance Abuse, Columbia University. XR-NTX is a unique formulation that offers patients and physicians a once-monthly, non-addictive medication to help fight this challenging disease.

Medical treatment for opioid dependence is an established and growing pharmaceutical market, yet there are limitations with currently available therapies," stated Richard Pops, Chief Executive Officer of Alkermes. We look forward to expanding our label beyond alcohol dependence to make XR-NTX available as the first and only non-narcotic, non-addictive, once-monthly treatment option for the millions of patients struggling with opioid dependence.

Alkermes will complete the full analysis of the phase 3 trial data and plans to submit the data for publication in a peer-reviewed journal.

SOURCE Alkermes, Inc.